Vyome Therapeutics
Delhi · Founded 2010
About Vyome Therapeutics
Vyome Biosciences is an innovation-driven company, with a vision to develop novel drugs for antibiotics-resistant acne and other opportunist pathogens through a unique pipeline of antibiotics that retard resistance development. Vyome’s development platform is completely risk mitigated. Vyome has a deep pipeline of IP based products targeting multiple indications. The *lead molecule (VB 1953)*, which targets the huge unmet need in the drug resistant acne prescription market, will be entering the clinical phase with *USFDA IND Application Filing in Q4 2015*. Vyome has state-of-the-art infrastructure facilities to carry out all its research and lab development work, with full-fledged formulation, analytical, chemistry, biology & molecular biology, clinical and the regulatory divisions. The infrastructure and the team enables Vyome to conceive ideas, develop them and commercialize them at a rapid pace.
Company Facts
- Founded: 2010
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $83.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: nasdaq:HIND
- Website: https://www.vyometx.com/
- Phone: 01143034661
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/vyome-therapeutics-17486 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.